The spleen in liver cirrhosis: revisiting an old enemy with novel targets.
The spleen in liver cirrhosis: revisiting an old enemy with novel targets.
复制标题
肝硬化中的脾脏：以新靶点重访宿敌
DOI：
10.1186/s12967-017-1214-8
复制
发表时间：
2017-05-23
影响因子：
7.4
通讯作者：
Li Z
中科院分区：
文献类型：
--
作者：
Li L;Duan M;Chen W;Jiang A;Li X;Yang J;Li Z
脾脏是一个次级淋巴器官，可以影响多种疾病的进展，特别是肝硬化。在慢性肝病中，脾肿大和脾功能亢进可随着门静脉高压症的发展而显现。这些脾脏异常与肝纤维化向肝硬化的进展有关，尽管确切的机制仍知之甚少。本文从肝纤维化、免疫微环境失调和肝再生三个方面综述了脾肿大和脾功能亢进在肝硬化发生发展中的作用机制。最后，我们讨论了可能的治疗策略，调节脾脏异常，包括新的潜在用途的纳米药物在非手术靶向脾脏疾病治疗肝硬化。
The spleen is a secondary lymphoid organ which can influence the progression of multiple diseases, notably liver cirrhosis. In chronic liver diseases, splenomegaly and hypersplenism can manifest following the development of portal hypertension. These splenic abnormalities correlate with and have been postulated to facilitate the progression of liver fibrosis to cirrhosis, although precise mechanisms remain poorly understood. In this review, we summarize the literature to highlight the mechanistic contributions of splenomegaly and hypersplenism to the development of liver cirrhosis, focusing on three key aspects: hepatic fibrogenesis, hepatic immune microenvironment dysregulation and liver regeneration. We conclude with a discussion of the possible therapeutic strategies for modulating splenic abnormalities, including the novel potential usage of nanomedicine in non-surgically targetting splenic disorders for the treatment of liver cirrhosis.